---
title: 'Life Sciences Daily Summary: What Happened on November 15, 2026'
headline: FDA rejects Summit and Akeso’s ivonescimab for lung cancer
description: The decision turns on a gap between delaying disease progression and
  extending patients’ lives.
url: https://thebench.bio/news/summaries/2026-11-15
topic: all
date: '2026-11-15'
covers:
- '2026-11-15'
date_published: '2026-11-16T00:01:14Z'
date_modified: '2026-11-16T00:01:14Z'
tags:
- Regulatory
sources: 1
publisher: TheBench.Bio
---

# Life Sciences Daily Summary: What Happened on November 15, 2026

**FDA rejects Summit and Akeso’s ivonescimab for lung cancer**

The decision turns on a gap between delaying disease progression and extending patients’ lives.

## Today in brief

Summit said the FDA refused to approve ivonescimab, its lung cancer treatment developed with Akeso. [1] Reviewers said the drug’s effect on cancer progression did not offset its failure to extend patients’ lives in the FDA’s benefit-risk assessment. [1]

## FDA says ivonescimab did not show a survival benefit

Summit Therapeutics said the FDA rejected ivonescimab, which it developed with Akeso for a type of lung cancer. [1] In its letter to the companies, the FDA said the drug could not be approved because it had not extended patients’ lives. [1]

The treatment slowed the worsening of patients’ cancer, but FDA reviewers said that result did not establish a favorable benefit-risk profile without a survival benefit. [1]

## Sources

1. [STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics](<https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/?utm_campaign=rss>), STAT Biotech, 2026-11-15

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/?utm_campaign=rss>
